The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience (Q38675773)

5 September 2017

1 reference

title

The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience (English)

1 reference

5 September 2017

1 reference

Caroline van den Ende

object named as

Caroline Van Den Ende

1 reference

5 September 2017

Cinzia Marano

1 reference

5 September 2017

Ayla Van Ahee

1 reference

5 September 2017

Eveline M Bunge

1 reference

5 September 2017

Laurence De Moerlooze

1 reference

5 September 2017

publication date

2 June 2017

1 reference

Expert Review of Vaccines

5 September 2017

published in

1 reference

5 September 2017

1 reference

5 September 2017

1 reference

5 September 2017

page(s)

811-832

1 reference

A "NEW" ANTIGEN IN LEUKEMIA SERA

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

The global impact of vaccination against hepatitis B: a historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Correlates of protection induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

A review of the long-term protection after hepatitis A and B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Factors influencing immunologic response to hepatitis B vaccine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Early anti-HBs antibody response to accelerated and to conventional hepatitis B vaccination regimens in healthy persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis A/B vaccination of adults over 40 years old: comparison of three vaccine regimens and effect of influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Rapid immunization effects of a new type of 60 μg hepatitis B vaccine compared with traditional 20 μg hepatitis B vaccines in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

A new accelerated vaccination schedule for rapid protection against hepatitis A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Accelerated Schedule for Hepatitis B Immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunisation of staff of a regional blood transfusion centre with a recombinant hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Evaluation of immune response to Hepatitis B vaccine in health care workers at a tertiary care hospital in Pakistan: an observational prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

New hepatitis B vaccine formulated with an improved adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Factors influencing response to hepatitis B virus vaccination in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Vaccination against hepatitis B infection in patients with end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Comparison of hepatitis B surface antibody decay rates after vaccination between hemodialysis and peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis B Vaccination in HIV-Infected Youth: A Randomized Trial of Three Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Protective efficacy of a recombinant deoxyribonucleic acid hepatitis B vaccine in institutionalized mentally handicapped clients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Effect of age and frequency of injections on immune response to hepatitis B vaccination in drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Compliance and immunogenicity of two hepatitis B vaccination schedules in sex workers in Belgium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Compliance with and response to hepatitis B vaccination in remaining quilombo communities in Central Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis B vaccination coverage among high-risk adults 18–49 years, U.S., 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis B vaccination and the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Vaccinations and Risk of Central Nervous System Demyelinating Diseases in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Association of infectious mononucleosis with multiple sclerosis. A population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Nucleic acid testing to detect HBV infection in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

Are booster immunisations needed for lifelong hepatitis B immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2017.1338568

10.1080/14760584.2017.1338568

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference